Company expands its ADC pipeline and patent estate for novel, differentiated ADCsNew pipeline candidate AKTX-102 leverages ...
TECregen Appoints Drug Development Veteran Dr. Klaas P. Zuideveld as Chief Executive Officer to Lead Thymus Regeneration Platform into Clinical Development ...
Trade Brains on MSN
5 pharma stocks that are leading the cancer treatment revolution to keep on your radar
India, Jan. 24 -- With cancer incidence rising globally, several Indian pharmaceutical companies are strengthening their ...
Detailed price information for Aprea Therapeutics Inc (APRE-Q) from The Globe and Mail including charting and trades.
Basel, Switzerland / Munich, Germany, January 26, 2026 - NUCLIDIUM AG, a clinical-stage radiopharmaceutical company developing a proprietary copper-based theranostic platform, today announced that U.S ...
First patients dosed in DAYBreak™ registrational program for bexobrutideg in relapsed/refractory CLLPresented Phase 1 results at ASH 2025 that ...
Alpha Tau Medical targets major 2026 catalysts as Alpha DaRT gains momentum; key pancreatic & GBM readouts ahead. Read the full analysis here of DRTS stock.
The MarketWatch News Department was not involved in the creation of this content.-- Servier reported Group revenues of EUR6.9 billion for 2024/25, up 16.2% from 2023/24. -- Growth ...
Key Milestone Builds Toward Doubling Patent Portfolio to Over 200 Worldwide - Positioning Propanc as a Long-Term Leader in Metastatic Cancer Prevention ...
Appointment builds on CHF 10 million seed financing and Board leadership expansionBASEL, Switzerland, Jan. 29, 2026 /PRNewswire/ -- TECregen, a biotechnology company pioneering thymus rejuvenation ...
Poolbeg Pharma plc - Peer-Reviewed POLB 001 LPS Challenge Trial Paper Published in Frontiers in Immunology 28 January 2026- Poolbeg Pharma (AIM: POLB, 'Poolbeg' or the 'Company'), a clinical-stage ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results